ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026
[Evaluation of bilateral vaccine cooperation priority countries on Chinese human papillomavirus vaccine using hierarchical K-means hybrid clustering].
Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate priority target countries and formulate context-specific cooperation modalities for China ' s bilateral international collaboration on human papillomavirus (HPV) vaccines, thereby furnishing an evidence-based reference for optimizing China ' s bilateral vaccine cooperation stra-tegies and contributing to global health equity.
methodsUsing a previously established index system designed for selecting preferred countries in China ' s international vaccine cooperation, we comprehensively applied a weighted-scoring approach to quantitatively rank 29 Phases 3 and 4 Global Alliance for Vaccines and Immunization (Gavi) eligible countries in HPV vaccine cooperation. Based on 5 first-level index (legal and regulatory factors, economic factors, political factors, social factors, and technological factors) scores, a hierarchical K-means hybrid method was used for clustering the countries. Hierarchical clustering was initially utilized to explore the underlying data structure and determine the optimal number of clusters, followed by K-means clustering to precisely categorize the evaluated nations based on their multidimensional characteristics.
resultsThe top10 countries were mostly Asian countries. African countries were mostly in the lower ranks. The countries were clustered into three types: (1) Technology transfer priority (
conclusionIndonesia, Viet Nam, and Uzbekistan are identified as the priority target countries for China ' s bilateral international cooperation on HPV vaccines. For these technology-transfer priority nations, cooperation should be strategically conducted through diverse modalities encompassing vaccine product export, clinical trial collaboration, authorized licensing, and technology transfer.
Indexed as
Identifiers
42287037PMC13268818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.